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ulates erythropoiesis, which can be induced by anemia and
hypoxia, when partial pressure of oxygen in tissue de-
creases. In 1957, Jacobson first described the chief role of
kidneys in producing EPO after birth. Currently, using GFP
reporter mice, it was revealed that EPO is produced in the
kidney by fibroblast-like peritubular interstitial cells.
Among the renal cells, pericytes are interstitial collagen-
producing cells that have close contact with endothelial
cells in a normal kidney and, therefore, stand a good
chance of playing a critical role in sensing the oxygen
pressure and producing EPO in response to anemia and
hypoxia.1
The best understood regulating factor of the EPO gene
expression is hypoxia-inducible factor (HIF), a transcription
factor composed of a constitutively expressed b subunit and
an oxygen-regulated a subunit.2 Under normoxia, HIF-a is
hydroxylated at two prolyl residues by prolyl hydroxylation
domain proteins (PHDs), recognized by Von HippeleLindau
tumor suppressor protein, and then targeted for proteoso-
mal degradation. By contrast, HIF-a is stabilized in hypoxia
due to suppression of PHDs, is able to translocate into nu-
cleus, binds to hypoxia response element on EPO gene
corporately with HIF-b, and upregulates the expression
level of EPO.* Corresponding author. Graduate Institute of Physiology, College
of Medicine, National Taiwan University, Number 1, Jen-Ai Road,
Section 1, Taipei 100, Taiwan.
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http://dx.doi.org/10.1016/j.jfma.2013.04.005In healthy adults, EPO production can be induced by
anemia, with EPO concentrations increasing from 100-fold
to 1000-fold. In patients with chronic kidney disease (CKD)
who commonly suffer from anemia, although EPO can be
stimulated and sustained at a certain level, it fails to
compensate for the low hematocrit level. As renal function
deteriorates, hematocrit level decreases, which can be as
low as < 20%. This so-called “renal anemia” not only affects
cognitive abilities, immune responses, and the quality of
life, but also causes left ventricular hypertrophy and other
cardiovascular complications, finally becoming a risk factor
for survival. Ever since recombinant human EPO (rhEPO)
was synthesized and used in its first clinical trial in 1985,
rhEPO therapy has become the most prevailing strategy to
treat renal anemia. However, various responses to
erythropoiesis-stimulating agents have been observed in
patients. In addition, parenteral administration of rhEPO is
not only inconvenient, but also an economic burden, not to
mention that it may increase the risk of cardiovascular or
cerebrovascular accidents.3 Given the several limitations of
this major therapy used nowadays, other possible strategies
for treating renal anemia need to be developed.
Despite the reduction of EPO plasma concentration in
CKD patients, the oxygen-dependent regulating system of
EPO still functions. In 2008, a study analyzing the responses
of rhEPO treatment in 341,737 end-stage renal disease
patients pointed out that those living at higher altitudes
reached higher hematocrit levels with lower doses of
rhEPO. In 2010, Bernhardt et al4 found that FG-2216, a
PHD inhibitor and HIF stabilizer, was capable of stimulating
endogenous EPO production in hemodialysis patients
suffering from renal anemia. The elegant experiment& Formosan Medical Association. All rights reserved.
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but the aberrancy of oxygen sensing in CKD patients that
results in renal anemia, and hinted that manipulation of the
HIF system might be a promising strategy for revival of EPO
production in CKD patients. Nevertheless, activation of the
HIF system can cause unpredictable effects, for instance,
upregulation of vascular endothelial cell growth may lead
to angiogenesis, promoting growth of tumors. Hence,
alternative ways to revive EPO production in CKD patients
need to be identified.
In progression of CKD, renal fibrosis is a common
pathway regardless of the initiated injuries. It is charac-
terized by infiltration of inflammatory cells, atrophy of
tubular cells, activation of fibroblasts, and deposition of
the extracellular matrix (ECM). Our previous studies have
proved that during the progression of renal fibrosis, peri-
cytes transdifferentiate into myofibroblasts, produce
collagen-rich extracellular matrix, and result in irreversible
renal fibrosis.1 Given the aptitude of pericytes for sensing
oxygenic variation and expressing EPO, and that the EPO-
producing capabilities remain in fibrotic kidney, it is
possible that the hypoxia-inducible EPO-producing abilities
are abated during the pericyteemyofibroblast transition,
leading to inadequate EPO secretion in fibrotic kidneys of
CKD patients.
DNA methylation, a kind of epigenetic modification, is
one of the probable mechanisms underlying inadequate
EPO production in CKD patients. In hepatoma cell line, a
methylation-free HIF binding site of EPO 30 enhancer is
indispensable for hypoxia-induced EPO expression.5 A study
in 2000 further revealed a CpG island harboring in promoter
and 50-untranslated region of human EPO gene; whose
expression is inversely correlated with the methylation
level of CpG Island.6 Also, Steinmann et al7 found that the
CpG islands in promoter and enhancer of EPO were hyper-
methylated in several cancer cell lines, resulting in a
reduction in EPO expression. Recently, Bechtel et al8
demonstrated that perpetuation of renal fibrosis in the
kidney is caused by the hypermethylation of RASAL1, which
encodes Ras oncoprotein inhibitor. Additionally, they found
that the epigenetic change is mediated by DNA methyl-
transferase 1, which is upregulated in most of the fibro-
blasts in a fibrotic kidney.
According to previous findings, we hypothesize that the
insufficient EPO production may be caused by the increasedDNA methyltransferase when pericytes transdifferentiate
into myofibroblasts in fibrotic kidney, contributing to the
hypermethylation of EPO regulatory sequence and silencing
of EPO gene. Further studies should be conducted to
confirm the causal relationship between methylation and
expression of EPO gene using an animal model of kidney
fibrosis. If possible, DNA demethylating agents may be
chosen to revive EPO production in CKD patients. The more
clearly the mechanism underlying inadequate EPO produc-
tion is identified, the closer an avenue to the renaissance of
EPO production in diseased kidneys we get to.Acknowledgments
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